Zymeworks Reports the US FDA’s IND Clearance of ZW191 for Treating Solid Tumors
Shots:
- The US FDA has cleared the IND application of ZW191 and anticipates initiating the clinical evaluations of ZW191 and ZW171 later in 2024
- ZW191 is developed through the company's drug conjugate platforms & TOPO1i-based payload technology ZD06519, for FR⍺-expressing tumors such as ovarian & gynecological cancers as well as NSCLC. ZW191 has also shown strong anti-tumor activity and safety in preclinical models
- The company plans to seek regulatory authorization to begin clinical studies for ZW191 outside the US in H2’24. IND filings for ZW220 (NaPi2b ADC) & ZW251 (GPC3 ADC) are anticipated in 2025
Ref: Zymeworks | Image: Zymeworks
Related News:- Zymeworks Reports the NMPA’s BLA Acceptance of Zanidatamab to Treat Biliary Tract Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
